Rein Therapeutics announces preliminary blinded Phase 2 Renew data
RNTX•Rein Therapeutics announced preliminary blinded Phase 2 Renew data showing encouraging lung function trends in patients with idiopathic pulmonary fibrosis and reported third-quarter 2026 financial results.




